Suchen
Anbio Biotechnology
NNNNZur Watchlist hinzufügen
9.900USD
-0.850-7.91%
Handelsschluss 07-31 16:00（ET）Kurse um 15 Minuten verzögert
434.52MMarktkapitalisierung
67.52KGV TTM
mehr Informationen über Anbio Biotechnology Unternehmen
Anbio Biotechnology is a Germany-based medical device company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).
Anbio Biotechnology Informationen
BörsenkürzelNNNN
Name des UnternehmensAnbio Biotechnology
IPO-datumFeb 19, 2025
CEOLau (Michael)
Anzahl der mitarbeiter27
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 19
AddresseFriedrich-Ebert-Anlage 49
StadtFRANKFURT AM MAIN
BörseNASDAQ OMX - NASDAQ BASIC
LandGermany
Postleitzahl60308
Telefon4916096247281
Websitehttps://anbiobiotechnology.com/
BörsenkürzelNNNN
IPO-datumFeb 19, 2025
CEOLau (Michael)
Führungskräfte von Anbio Biotechnology
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael Lau
Mr. Michael Lau
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Suki Song
Ms. Suki Song
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Chris Tiantian
Mr. Chris Tiantian
Chief Business Officer
Chief Business Officer
--
--
Mr. Cany Xu
Mr. Cany Xu
Executive Director
Executive Director
--
--
Ms. Nancy Hartzler
Ms. Nancy Hartzler
Independent Director
Independent Director
--
--
Mr. Kenneth Li
Mr. Kenneth Li
Independent Director
Independent Director
--
--
Mr. David Hsu
Mr. David Hsu
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael Lau
Mr. Michael Lau
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Suki Song
Ms. Suki Song
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Chris Tiantian
Mr. Chris Tiantian
Chief Business Officer
Chief Business Officer
--
--
Mr. Cany Xu
Mr. Cany Xu
Executive Director
Executive Director
--
--
Ms. Nancy Hartzler
Ms. Nancy Hartzler
Independent Director
Independent Director
--
--
Mr. Kenneth Li
Mr. Kenneth Li
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Anbio Biotechnology?
Die fünf größten Anteilseigner von Anbio Biotechnology sind: Mr. Michael Lau
Wie viele Institutionen halten Anteile an Anbio Biotechnology (NNNN)?
Mit Stand vom 2026Q1 halten 13 Institutionen Anteile an Anbio Biotechnology, mit einem Gesamtmarktwert von etwa 2.13M, was 4.86% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 2063041.00 gestiegen.